Ameritas Advisory Services LLC Has $2.37 Million Position in Johnson & Johnson $JNJ

Ameritas Advisory Services LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 31.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 12,770 shares of the company’s stock after selling 5,956 shares during the quarter. Ameritas Advisory Services LLC’s holdings in Johnson & Johnson were worth $2,368,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Abich Financial Wealth Management LLC bought a new stake in Johnson & Johnson in the 3rd quarter valued at approximately $26,000. Evolution Wealth Management Inc. bought a new position in Johnson & Johnson during the second quarter worth about $27,000. Clayton Financial Group LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $28,000. Semmax Financial Advisors Inc. raised its position in shares of Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares during the period. Finally, Compass Financial Services Inc raised its holdings in Johnson & Johnson by 707.1% in the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock valued at $42,000 after acquiring an additional 198 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.5%

JNJ stock opened at $243.37 on Friday. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $246.35. The stock’s 50 day simple moving average is $217.25 and its 200 day simple moving average is $196.39. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.80 and a current ratio of 1.03. The company has a market cap of $586.36 billion, a P/E ratio of 22.02, a price-to-earnings-growth ratio of 2.37 and a beta of 0.35.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The business had revenue of $24.28 billion during the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. On average, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson’s payout ratio is presently 47.06%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on JNJ. Guggenheim lifted their target price on Johnson & Johnson from $227.00 to $240.00 and gave the stock a “buy” rating in a report on Friday, January 23rd. Sanford C. Bernstein raised their price objective on Johnson & Johnson from $208.00 to $225.00 and gave the company a “market perform” rating in a research note on Friday, January 23rd. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a report on Monday, January 5th. BMO Capital Markets reiterated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Finally, Royal Bank Of Canada upped their price target on Johnson & Johnson from $240.00 to $255.00 and gave the company an “outperform” rating in a research report on Tuesday, February 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $233.73.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.